The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Victor Manuel Villalobos
Employment - Janssen Oncology
Consulting or Advisory Role - Abbvie; Agios; Blueprint Medicines; Daiichi Sankyo; Epizyme; Ignyta; Janssen; Lilly; NanoCarrier; Novartis; Springworks Therapeutics
Travel, Accommodations, Expenses - Epizyme; GenMab; Janssen; Lilly; Xencor
 
Nadia Hindi
Honoraria - PharmaMar
Research Funding - Adaptimmune (Inst); Amgen (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daychii (Inst); Deciphera (Inst); Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Brian Andrew Van Tine
Leadership - Polaris
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Bayer; Cytokinetics; Daiihi Sankyo; Deciphera; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Lilly; Novartis; Pfizer
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Andrew J. Wagner
Honoraria - Deciphera
Consulting or Advisory Role - Daiichi Sankyo; Deciphera; Five Prime Therapeutics; Lilly; Mundipharma; Nanocarrier
Research Funding - AADi (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst)
 
Bartosz Chmielowski
Consulting or Advisory Role - Deciphera; Epizyme; Genentech; IDEAYA Biosciences; Iovance Biotherapeutics; Nektar; OncoSec; Sanofi
Speakers' Bureau - Sanofi/Regeneron
Research Funding - Advenchen Laboratories (Inst); Aeglea Biotherapeutics (Inst); Array BioPharma (Inst); Ascentage Pharma (Inst); Atreca (Inst); Biothera (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); IDEAYA Biosciences (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Neon Therapeutics (Inst); Novartis (Inst); PACT Pharma (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Rgenix (Inst); Tolero Pharmaceuticals (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Deciphera; Epizyme; Regeneron
 
Donna Elise Levy
Employment - Syneos Health
Stock and Other Ownership Interests - Pfizer; Syneos Health
 
Matteo Ceccarelli
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Honoraria - Lilly
Travel, Accommodations, Expenses - Lilly
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Karma Oncology; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Mark Andrew Dickson
Consulting or Advisory Role - Celgene
Research Funding - AADi (Inst); Lilly (Inst)